ArticleAnti-cancer drugs2017

Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.

Junfei Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.